Original Article
Modern Pathology (2005) 18, 541–546, advance online publication, 29 October 2004; doi:10.1038/modpathol.3800321
Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential
Mauro Papotti1, Jaime Rodriguez2, Roberta De Pompa1, Armando Bartolazzi3 and Juan Rosai2
- 1Department of Clinical and Biological Sciences, University of Turin and St Luigi Hospital, Orbassano, Turin, Italy
- 2Division of Pathology, National Cancer Institute, Milan, Italy
- 3Division of Pathology, St Andrea Hospital, Rome, Italy
Correspondence: Dr M Papotti, MD, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Torino, Italy. E-mail: mauro.papotti@unito.it
Received 12 April 2004; Revised 17 September 2004; Accepted 17 September 2004; Published online 29 October 2004.
Abstract
Well-differentiated encapsulated tumors of the thyroid gland with a follicular architecture may cause diagnostic difficulties. Questionable vascular or capsular penetration may raise the possibility of a follicular carcinoma, while focal nuclear clearing and grooves may suggest a diagnosis of papillary carcinoma. A proposal has recently been made to designate cases showing suggestive but not conclusive morphological evidence of malignancy along these lines as well-differentiated or follicular tumors of uncertain malignant potential. The aim of the present study was to investigate the expression and diagnostic role in well-differentiated or follicular tumors of uncertain malignant potential of Galectin-3 and HBME-1, two malignancy-related markers. A total of 21 tumors fulfilling the criteria of well-differentiated or follicular tumors of uncertain malignant potential were collected from two institutions, including eight cases with questionable vascular and/or capsular invasion and 13 cases with some degree of nuclear changes in the form of clearing, grooves, and/or pseudoinclusions. Tumors in the first group expressed HBME-1 and Galectin-3 focally (less than 25% of tumor cells) in 5/8 and 3/8 cases, respectively, with 62.5% of cases reacting for at least one marker. Cases in the second category expressed HBME-1 and Galectin-3 in 9/13 and 10/13 cases, respectively, with 92.3% of cases having at least one marker expressed. These findings indicate that HBME-1 and Galectin-3 are heterogeneously distributed in these borderline tumors, but that a strong and diffuse expression of HBME-1 and to a lower extent of Galectin-3 was preferentially observed in the group characterized by nuclear changes which were similar but less developed than those of conventional papillary carcinoma. The relationship found between the markers investigated and these nuclear changes suggests that the tumors containing them are pathogenetically linked to papillary carcinomas.
Keywords:
follicular carcinoma, Galectin-3, HBME-1, papillary carcinoma, thyroid, tumor of uncertain malignant potential (UMP)
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Cancer after nuclear fallout: lessons from the Chernobyl accident
Nature Reviews Cancer Perspective (01 Jul 2002)
RESEARCH
British Journal of Cancer Original Article
British Journal of Cancer Original Article
Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma
Modern Pathology Original Article
Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy
Oncogene Original Article

